FIELD: chemical and pharmaceutical industry.
SUBSTANCE: invention relates to lyophilized pharmaceutical immunocytokine composition including immunocytokine and containing as cytokine component interleukin-2 (IL-2), sugar or aminosugar, amino acid and surfactant, wherein said composition contains: immunocytokines from 0.1 to 25 mg/ml; sugar or aminosugar 1-200 mg/ml; amino acid 1-200 mMol/l; and surfactant 0.001-1 mass %.
EFFECT: composition for parantheral administering with prolonged storage time even at increased temperatures.
13 cl, 8 ex, 4 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FREEZE-DRIED PREPARATION, ANTIBODY-CONTAINING AGAINST EGF RECEPTOR | 2002 |
|
RU2339402C2 |
| PHARMACEUTICAL PREPARATION CONTAINING EGF RECEPTOR ANTIBODY | 2004 |
|
RU2381036C2 |
| ENHANCEMENT OF IMMUNE RESPONSE WHEREIN FUSED PROTEIN ANTIBODY-CYTOKINE IS MEDIATOR BY COMBINED TREATMENT WITH AGENTS INCREASING IMMUNOCYTOKINE ABSORPTION | 2001 |
|
RU2272644C2 |
| PHARMACEUTICAL COMPOSITION OF FUSION PROTEIN TACI-FC | 2020 |
|
RU2779387C1 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| ANTIVIRAL AND ANTIMICROBIAL COMPOSITION | 2008 |
|
RU2457857C2 |
| STABLE COMPOSITION OF ANTIBODY SPECIFICALLY BOUND WITH HER2 RECEPTORS AND PREPARATION METHOD THEREOF | 2014 |
|
RU2589691C2 |
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
| ANTIVIRAL AND ANTIMICROBIAL COMPOSITION | 2008 |
|
RU2457855C2 |
| AQUEOUS SOLUTION OF PHARMACEUTICAL COMPOSITION OF 20(R)-GINSENOSIDE Rg3 AND METHOD FOR PREPARING IT | 2007 |
|
RU2432164C2 |
